Synthetic Biology: Emerging Global Markets
November 17, 2011
Wellesley, Mass. – In a recent release, SYNTHETIC BIOLOGY: EMERGING GLOBAL MARKETS (BIO066B) from BCC Research (www.bccresearch.com), the global value of the synthetic biology market totals over $1.6 billion for 2011, and is expected to reach $10.8 billion in 2016, increasing at a compound annual growth rate (CAGR) of 45.8%.
The global synthetic biology market can be broken down into three segments – Enabled products, core products, and enabling products.
Enabling technologies and products are used as the engine that drives the development of the synthetic biology industry.
Core products and technologies — standardized DNA parts, synthetic genes, and chassis organisms — are the key tools by which cellular factories and systems produce enabled products.
Synthetic biology enabled products — pharmaceuticals, diagnostics, chemicals, biofuels, and agricultural — target large downstream market opportunities. Each of these downstream markets is worth tens of billions of dollars annually.
Enabled products, the largest market segment, is estimated at $1.4 billion in 2011 and will grow at a forecasted CAGR of 46.5% to reach nearly $9.5 billion in 2016.
The values of enabling and core products, respectively, are estimated at $110.9 and $126.8 million in 2011, with projected market sizes of $653.7 and $698.8 million in 2016, and will grow at CAGRs of 42.6% and 40.7%.
It is important for companies in industries affected by the developments in synthetic biology to sort through the many potential applications to identify near-term commercial opportunities for product development focus. This report allows companies to prioritize product opportunities, establishing a solid framework for strategic planning.
The report will be of particular interest to pharmaceuticals, chemicals, enzymes, energy, agricultural, biotechnology, and bionanobiotechnology companies, as well as suppliers of genomics tools, DNA synthesis, and DNA sequencing products. It will also be of high interest to professionals within governments and regulatory agencies to understand the scope and pace of synthetic biology technologies as they reach the market.
Synthetic Biology: Emerging Global Markets( BIO066B )
Publish Date: Nov 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum